Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in var...
Sábháilte in:
Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Béarla |
Foilsithe / Cruthaithe: |
2021
|
Rochtain ar líne: | https://doi.org/10.1371/journal.pmed.1003872 https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003872&type=printable |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|